Your SlideShare is downloading. ×
Hodgkin, Mantle Cell, Follicular & Natural Killer Cell Lymphoma Therapeutic Review H1 2013
Hodgkin, Mantle Cell, Follicular & Natural Killer Cell Lymphoma Therapeutic Review H1 2013
Hodgkin, Mantle Cell, Follicular & Natural Killer Cell Lymphoma Therapeutic Review H1 2013
Hodgkin, Mantle Cell, Follicular & Natural Killer Cell Lymphoma Therapeutic Review H1 2013
Hodgkin, Mantle Cell, Follicular & Natural Killer Cell Lymphoma Therapeutic Review H1 2013
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Hodgkin, Mantle Cell, Follicular & Natural Killer Cell Lymphoma Therapeutic Review H1 2013

137

Published on

Buy the report "Hodgkin, Mantle Cell, Follicular & Natural Killer Cell Lymphoma Therapeutic Review H1 2013" at US $2000 for a Single User PDF License from RnR Market Research Reports Library.

Buy the report "Hodgkin, Mantle Cell, Follicular & Natural Killer Cell Lymphoma Therapeutic Review H1 2013" at US $2000 for a Single User PDF License from RnR Market Research Reports Library.

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
137
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. RnR Market Research Offers “Hodgkin, Mantle Cell, Follicular & Natural Killer CellLymphoma Therapeutic Review H1 2013” Report at US$ 2000 (Single User License). Thereport got published in Feb 2013.Global Markets Direct’s, ‘Hodgkin, Mantle Cell, Follicular & Natural Killer Cell Lymphoma – PipelineReview, H1 2013′, provides an overview of the indication’s therapeutic pipeline. This report providesinformation on the therapeutic development for Hodgkin, Mantle Cell, Follicular & Natural Killer CellLymphoma, complete with latest updates, and special features on late-stage and discontinued projects. Italso reviews key players involved in the therapeutic development for Hodgkin, Mantle Cell, Follicular &Natural Killer Cell Lymphoma. Hodgkin, Mantle Cell, Follicular & Natural Killer Cell Lymphoma – PipelineReview, Half Year is built using data and information sourced from Global Markets Direct’s proprietarydatabases, Company/University websites, SEC filings, investor presentations and featured press releasesfrom company/university sites and industry-specific third party sources, put together by Global MarketsDirect’s team.Scope- A snapshot of the global therapeutic scenario for Hodgkin, Mantle Cell, Follicular & Natural Killer CellLymphoma.- A review of the Hodgkin, Mantle Cell, Follicular & Natural Killer Cell Lymphoma products underdevelopment by companies and universities/research institutes based on information derived fromcompany and industry-specific sources.- Coverage of products based on various stages of development ranging from discovery till registrationstages.- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.- Coverage of the Hodgkin, Mantle Cell, Follicular & Natural Killer Cell Lymphoma pipeline on the basis ofroute of administration and molecule type.- Key discontinued pipeline projects.- Latest news and deals relating to the products.Get a Report Copy of Natural Killer Cell Lymphomas @ http://www.rnrmarketresearch.com/natural-killer-cell-lymphomas-pipeline-review-h1-2013-market-report.htmlGet a Report Copy of Follicular Lymphomas @ http://www.rnrmarketresearch.com/follicular-lymphoma-pipeline-review-h1-2013-market-report.htmlReasons to buy- Identify and understand important and diverse types of therapeutics under development for Hodgkin,Mantle Cell, Follicular & Natural Killer Cell Lymphoma.- Identify emerging players with potentially strong product portfolio and design effective counter-strategiesto gain competitive advantage.- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.- Devise corrective measures for pipeline projects by understanding Hodgkin, Mantle Cell, Follicular &Natural Killer Cell Lymphoma pipeline depth and focus of Indication therapeutics.- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with themost attractive projects to enhance and expand business potential and scope.- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors thatdrove them from pipeline.Get a Report Copy of Mantle Cell Lymphomas @ http://www.rnrmarketresearch.com/mantle-cell-lymphoma-pipeline-review-h1-2013-market-report.html
  • 2. Get a Report Copy of Hodgkin @ http://www.rnrmarketresearch.com/hodgkin-lymphoma-pipeline-review-h1-2013-market-report.htmlTable of ContentTable of Contents 2List of Tables 4List of Figures 5Introduction 6Global Markets Direct Report Coverage 6Hodgkin Lymphoma Overview 7Therapeutics Development 8An Overview of Pipeline Products for Hodgkin Lymphoma 8Hodgkin Lymphoma Therapeutics under Development by Companies 10Hodgkin Lymphoma Therapeutics under Investigation by Universities/Institutes 13Late Stage Products 15Comparative Analysis 15Mid Clinical Stage Products 16Comparative Analysis 16Early Clinical Stage Products 17Comparative Analysis 17Discovery and Pre-Clinical Stage Products 18Comparative Analysis 18Hodgkin Lymphoma Therapeutics - Products under Development by Companies 19Hodgkin Lymphoma Therapeutics - Products under Investigation by Universities/Institutes 21Companies Involved in Hodgkin Lymphoma Therapeutics Development 23Seattle Genetics, Inc. 23Merck & Co., Inc. 24Gamida Cell Ltd. 25Infinity Pharmaceuticals, Inc. 26Plexxikon Inc. 27Novartis AG 28Cell Therapeutics, Inc. 294SC AG 30Hana Biosciences, Inc. 31MethylGene Inc 32Cytokinetics, Inc 33Spectrum Pharmaceuticals, Inc. 34Affimed Therapeutics AG 35Actinium Pharmaceuticals, Inc. 36Philogen S.p.A. 37Stemline Therapeutics, Inc. 38Syndax Pharmaceuticals, Inc. 39Xencor, Inc. 40TaiGen Biotechnology Co., Ltd. 41Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 42Lees Pharmaceutical Holdings Limited 43Hodgkin Lymphoma - Therapeutics Assessment 44Assessment by Monotherapy Products 44Assessment by Combination Products 45Assessment by Route of Administration 46
  • 3. Assessment by Molecule Type 48Drug Profiles 51StemEx - Drug Profile 51entinostat - Drug Profile 53pacritinib - Drug Profile 55brentuximab vedotin - Drug Profile 57brentuximab vedotin - Drug Profile 60brentuximab vedotin - Drug Profile 63mocetinostat - Drug Profile 66vinorelbine tartrate - Drug Profile 68panobinostat - Drug Profile 70everolimus - Drug Profile 73lucatumumab - Drug Profile 764SC-201 - Drug Profile 784SC-201 - Drug Profile 82SB-743921 - Drug Profile 86SL-101 - Drug Profile 88pralatrexate - Drug Profile 89AFM-13 - Drug Profile 92XmAb-2513 - Drug Profile 93belinostat + [bortezomib] - Drug Profile 94clioquinol - Drug Profile 95bevacizumab + [bleomycin sulfate] + [dacarbazine] + [doxorubucin] + [vinblastine sulfate] - Drug Profile96everolimus + panobinostat - Drug Profile 97Therapeutic allogeneic lymphocytes program - Drug Profile 99LMP-Specific Cytotoxic T-Lymphocytes - Drug Profile 100PLX-3397 - Drug Profile 101TG-0054 - Drug Profile 103SCH-900776 + [gemcitabine hydrochloride] - Drug Profile 105galiximab - Drug Profile 106bortezomib + [filgrastim] + [ifosfamide] + [vinorelbine tartrate] - Drug Profile 107ofatumumab + [cisplatin] + [cytarabine] + [etoposide] + [methylprednisolone] + Autologous Stem CellTransplantation - Drug Profile 108Autologous CAR.CD30 EBV Specific Cytotoxic T Lymphocytes - Drug Profile 110Therapeutic tumor infiltrating lymphocytes program - Drug Profile 111Therapeutic tumor infiltrating lymphocytes program - Drug Profile 113obinutuzumab + [cyclophosphamide] + [doxorubicin] + [fludarabine] + [prednisone] [INN] + [vincristine] -Drug Profile 115LMP Specific Cytotoxic T-Lymphocytes - Drug Profile 118IPI-145 - Drug Profile 119LMP-400 - Drug Profile 121LMP-776 - Drug Profile 123L19-I131 - Drug Profile 125JNJ-40346527 - Drug Profile 127Basiliximab + [Carmustine] + [Etoposide] + [Cytarabine] + [Melphalan] + Autologous Hematopoietic StemCell Transplantation - Drug Profile 128Allogeneic Donor Derived Lmp Specific Cytotoxic T-Lymphocyte - Drug Profile 129procarbazine hydrochloride - Drug Profile 130Iomab-B - Drug Profile 131Genetically Modified T Cell - Drug Profile 132Lymphoma Therapy - Drug Profile 133
  • 4. Hodgkin Lymphoma Therapeutics - Drug Profile Updates 134Hodgkin Lymphoma Therapeutics - Discontinued Products 194Hodgkin Lymphoma Therapeutics - Dormant Products 195Hodgkin Lymphoma - Product Development Milestones 198Featured News & Press Releases 198Appendix 209Methodology 209Coverage 209Secondary Research 209Primary Research 209Expert Panel Validation 209Contact Us 210Disclaimer 210List of TablesNumber of Products Under Development for Hodgkin Lymphoma, H1 2013 12Products under Development for Hodgkin Lymphoma - Comparative Analysis, H1 2013 13Number of Products under Development by Companies, H1 2013 15Number of Products under Development by Companies, H1 2013 (Contd..1) 16Number of Products under Investigation by Universities/Institutes, H1 2013 18Comparative Analysis by Late Stage Development, H1 2013 19Comparative Analysis by Mid Clinical Stage Development, H1 2013 20Comparative Analysis by Early Clinical Stage Development, H1 2013 21Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 22Products under Development by Companies, H1 2013 23Products under Development by Companies, H1 2013 (Contd..1) 24Products under Investigation by Universities/Institutes, H1 2013 25Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 26Seattle Genetics, Inc., H1 2013 27Merck & Co., Inc., H1 2013 28Gamida Cell Ltd., H1 2013 29Infinity Pharmaceuticals, Inc., H1 2013 30Plexxikon Inc., H1 2013 31Novartis AG, H1 2013 32Cell Therapeutics, Inc., H1 2013 334SC AG, H1 2013 34Hana Biosciences, Inc., H1 2013 35MethylGene Inc, H1 2013 36Cytokinetics, Inc, H1 2013 37Spectrum Pharmaceuticals, Inc., H1 2013 38Affimed Therapeutics AG, H1 2013 39Actinium Pharmaceuticals, Inc., H1 2013 40Philogen S.p.A., H1 2013 41Stemline Therapeutics, Inc., H1 2013 42Syndax Pharmaceuticals, Inc., H1 2013 43Xencor, Inc., H1 2013 44TaiGen Biotechnology Co., Ltd., H1 2013 45Johnson & Johnson Pharmaceutical Research & Development, L.L.C., H1 2013 46Lees Pharmaceutical Holdings Limited, H1 2013 47Assessment by Monotherapy Products, H1 2013 48Assessment by Combination Products, H1 2013 49Assessment by Stage and Route of Administration, H1 2013 51
  • 5. Assessment by Stage and Molecule Type, H1 2013 54Hodgkin Lymphoma Therapeutics - Drug Profile Updates 138Hodgkin Lymphoma Therapeutics - Discontinued Products 198Hodgkin Lymphoma Therapeutics - Dormant Products 199Hodgkin Lymphoma Therapeutics - Dormant Products (Contd..1) 200Hodgkin Lymphoma Therapeutics - Dormant Products (Contd..2) 201List of FiguresNumber of Products under Development for Hodgkin Lymphoma, H1 2013 12Products under Development for Hodgkin Lymphoma - Comparative Analysis, H1 2013 13Products under Development by Companies, H1 2013 14Products under Investigation by Universities/Institutes, H1 2013 17Late Stage Products, H1 2013 19Mid Clinical Stage Products, H1 2013 20Early Clinical Stage Products, H1 2013 21Discovery and Pre-Clinical Stage Products, H1 2013 22Assessment by Monotherapy Products, H1 2013 48Assessment by Combination Products, H1 2013 49Assessment by Route of Administration, H1 2013 50Assessment by Stage and Route of Administration, H1 2013 51Assessment by Molecule Type, H1 2013 52Assessment by Stage and Molecule Type, H1 2013 53For more details contact Mr. Priyank Tiwari: sales@rnrmarketresearch.com / +18883915441Website: http://www.rnrmarketresearch.com/

×